We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Speaker: Dr. Bruno Sarmento, Head of Infrastructure - i3S Board of Directors-Institute of Research and Innovation in Health, University of Porto, Portugal
Inflammatory Bowel Disease (IBD) is a chronic inflammatory condition affecting the gastrointestinal tract (GIT). The pathophysiology of IBD is multifaceted, driven by a complex interplay of genetic, environmental, and immune factors, and is featured by high variability among patients. This complexity makes the disease unpredictable and the treatment particularly challenging. Current therapies often lack precision, failing to target the inflamed areas directly, which results in reduced effectiveness and significant side effects. Stimulus-responsive nanoparticles (NPs) can deliver therapeutics directly to inflamed sites, boosting efficacy and minimizing exposure to the rest of the body. This approach improves treatment outcomes and reduces side effects, offering a major advancement in IBD management. Among these, ROS-sensitive nanosystems are the most effective, as elevated ROS levels are a common feature in inflamed tissues of IBD patients despite individual variations.
Host: Dr. Fernanda Raquel Da Silva Andrade, Main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Online attendance: https://gencat.zoom.us/j/81778755239
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.